Shopping Cart
- Remove All
- Your shopping cart is currently empty
COX-2-IN-31 (compound 7b) is an orally active dual inhibitor targeting COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM), and also inhibits transmembrane hCA IX (Ki=48.9 nM) and hCA XII (Ki=5.8 nM), demonstrating anti-inflammatory and analgesic activity [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | COX-2-IN-31 (compound 7b) is an orally active dual inhibitor targeting COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM), and also inhibits transmembrane hCA IX (Ki=48.9 nM) and hCA XII (Ki=5.8 nM), demonstrating anti-inflammatory and analgesic activity [1]. |
Targets&IC50 | COX-1:12.5 μM, COX-2:60 nM |
In vitro | In the carbonic anhydrase inhibition assay, COX-2-IN-31 (compound 7b) effectively inhibited hCA IX and XII with Kᵢ values within the nanomolar range (48.9 nM and 5.8 nM) [1]. |
In vivo | COX-2-IN-31 (compound 7b), administered orally at 10 mg/kg, demonstrated analgesic activity by significantly reducing writhing episodes in mice and decreasing paw edema height in carrageenan-induced rat paw edema tests while exhibiting gastric safety in albino male rats at this dose level [1]. |
Molecular Weight | 400.41 |
Formula | C17H16N6O4S |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.